Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Tilray Brands Inc (TLRY) vs Viatris Inc (VTRS) Price & Performance

Tilray Brands IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Tilray Brands Inc vs Viatris Inc — how do they compare? Tilray Brands Inc trades at $4.67 (market cap $649.42M), while Viatris Inc trades at $16.25 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 28.8× Tilray Brands Inc's market cap, and Viatris Inc pays a 2.95% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.

TLRYVTRS
Market Cap
$649.42M$18.69B
Sector
HealthHealth
52-Week High
$21.00$17.86
52-Week Low
$3.88$9.49
Enterprise Value
$816.55M$30.80B
Dividend Yield
2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Tilray Brands Inc

TLRY trades at $4.71, up 6.56% today, with a bullish technical signal from moving averages but mixed oscillators. Revenue grew to $821M in 2025, yet the company posted a net loss of -$2.19B, reflecting profitability challenges. Recent news highlights growth initiatives, including a partnership with Wolverhampton Wanderers and a new THC pouch launch. The stock remains volatile, with a low P/S of 0.58 and P/B of 0.4, suggesting potential undervaluation amid ongoing losses.

Outlook is cautious; TLRY's path to profitability hinges on revenue growth and cost management. Risks include persistent losses, high debt, and regulatory uncertainty. Analyst consensus is mixed, with 25% buy ratings but 65% hold, indicating skepticism. Investors should weigh growth potential against financial instability and market volatility.

Viatris Inc

Viatris (VTRS) trades at $16.28, down 0.91% on the day, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $3.51 billion in 2025 despite recent quarterly earnings beats, including Q2 2026 EPS of $0.69 versus $0.62 expected. Revenue declined to $14.30 billion in 2025, but operational cash flow remains strong at $2.32 billion. Recent news highlights divestitures and FDA approval for Gwyn Lo, a contraceptive patch.

Outlook is cautious due to persistent losses and high P/E of 236.2, but dividend payments and cost-cutting efforts offer stability. Risks include competitive pressures and debt levels, while analyst consensus leans hold. The stock's value hinges on margin improvement and debt reduction progress.

Returns comparison

Trailing returns across standard periods

About Tilray Brands Inc

Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.

Read more on TLRY

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS